JMP Securities analyst David Turkaly reiterated a Buy rating on Enovis (ENOV – Research Report) today and set a price target of $62.00.
David Turkaly has given his Buy rating due to a combination of factors, including Enovis’s strong financial performance and strategic positioning. The company reported impressive fourth-quarter results, exceeding expectations on both revenue and earnings per share. The Recon segment, in particular, demonstrated robust growth, with double-digit increases in hips, knees, and extremities sales worldwide.
Additionally, Enovis’s management provided optimistic guidance for 2025, projecting significant revenue and earnings growth. The company’s strategy to offer comprehensive care solutions enhances its market potential and long-term profitability. Furthermore, the successful integration of the Lima acquisition is expected to unlock further value, which Turkaly believes is not yet fully reflected in the stock’s current valuation.
In another report released today, Roth MKM also reiterated a Buy rating on the stock with a $75.00 price target.